Tech Company Inital Public Offerings

Caribou Biosciences IPO

Headquartered in Berkeley, Caribou Biosciences is now a public company.

Transaction Overview

Announced On
7/23/2021
Transaction Type
IPO
Amount
$304,000,000
Proceeds Purpose
We currently intend to use the proceeds to advance the clinical development of our CB-010 product candidate, including funding the ANTLER phase 1 clinical trial through initial data; fund IND-enabling activities and the potential initiation of clinical studies for our CB-011 and CB-012 product candidates; to continue research and development of our iPSC-to-NK platform for solid tumor-targeted cell therapies, advancement of our genome-editing technologies, as well as discovery-stage research toward potential additional programs; and the remainder for working capital and other general corporate purposes.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2929 7th St. 105
Berkeley, CA 94710
USA
Email Address
Overview
Caribou is a developer of cellular engineering and analysis solutions based on CRISPR technologies. Caribou's tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research.
Profile
Caribou Biosciences LinkedIn Company Profile
Social Media
Caribou Biosciences Company Twitter Account
Company News
Caribou Biosciences News
Facebook
Caribou Biosciences on Facebook
YouTube
Caribou Biosciences on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Rachel Haurwitz
  Rachel Haurwitz LinkedIn Profile  Rachel Haurwitz Twitter Account  Rachel Haurwitz News  Rachel Haurwitz on Facebook
Chief Financial Officer
Jason O'Byrne
  Jason O'Byrne LinkedIn Profile  Jason O'Byrne Twitter Account  Jason O'Byrne News  Jason O'Byrne on Facebook
Chief Scientific Officer
Steven Kanner
  Steven Kanner LinkedIn Profile  Steven Kanner Twitter Account  Steven Kanner News  Steven Kanner on Facebook
Vice President
Chris Fuller
  Chris Fuller LinkedIn Profile  Chris Fuller Twitter Account  Chris Fuller News  Chris Fuller on Facebook
Vice President
Justin Skoble
  Justin Skoble LinkedIn Profile  Justin Skoble Twitter Account  Justin Skoble News  Justin Skoble on Facebook
Vice President
Cherry Thomas
  Cherry Thomas LinkedIn Profile  Cherry Thomas Twitter Account  Cherry Thomas News  Cherry Thomas on Facebook
VP - Finance
Ryan Fischesser
  Ryan Fischesser LinkedIn Profile  Ryan Fischesser Twitter Account  Ryan Fischesser News  Ryan Fischesser on Facebook
VP - General Counsel
Barbara McClung
  Barbara McClung LinkedIn Profile  Barbara McClung Twitter Account  Barbara McClung News  Barbara McClung on Facebook
VP - Human Resources
Cindy Hayashi
  Cindy Hayashi LinkedIn Profile  Cindy Hayashi Twitter Account  Cindy Hayashi News  Cindy Hayashi on Facebook
VP - R & D
Scott Gradia
  Scott Gradia LinkedIn Profile  Scott Gradia Twitter Account  Scott Gradia News  Scott Gradia on Facebook
VP - Regulatory Affairs
Elaine Alambra
  Elaine Alambra LinkedIn Profile  Elaine Alambra Twitter Account  Elaine Alambra News  Elaine Alambra on Facebook


 

 

Browse more venture capital transactions:

Prev: 7/23/2021: Prodigal venture capital transaction
Next: 7/23/2021: Yoobic venture capital transaction

 

Share this article

 


About Our Venture Capital Transactions Database

We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary